Please assess the completion status of the following clinical trial:

Trial Title: A Study of Leukocytapheresis (LCAP) in Patients With Ulcerative Colitis (UC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed to have UC in the active stage based on clinical symptoms and findings from endoscopy~* Patients with pancolitis type or left-sided colitis type lesion of 15 cm or longer observed endoscopically~* Patients with Mayo score between 5 and 10~* Patients with Mayo sub-score (findings from flexible sigmoidoscopy) of 2 or 3~* Patients not having received any corticosteroids (referred to as steroids) (p.o., i.v., enema, suppository) within the past 6 weeks~Exclusion Criteria:~* Patients with a difficulty in peripheral vascular access~* Patients having received ACE inhibitor (at least 10 times of its half-life time for interval needed before initiating the treatment)~* Patients with toxic megacolon~* Patients with a malignant disease or its experience~* Patients with a severe cardiovascular disease (grade III or IV by the Classification of heart functions of the New York Heart Association (NYHA))~* Patients with a liver or kidney disease (AST(GOT) or ALT(GPT) or total bilirubin or creatinine level which is 2 or more times higher than the upper limit of normal (abbreviated as ULN, hereinafter)~* Patients suspected to have or having HBV or HCV or HIV or pathogenic bacteria~* Patients on anticoagulant therapy or with abnormality in the blood coagulation system (PT or PTT levels which are 1.5 or more times higher than ULN~* Pregnant women or patients with possible pregnancy~* Breast feeding women~* Patients weighing 40 kg or less~* Patients with hemoglobin level of less than 6.5 mmol/L (10.5 g/dL)~* Patients with platelet count of less than 150 x 103/mm3, 150 x 109/L (15 x 104/mm3)~* Patients with white blood cell count of less than 3.5 x 109/L (3,500/mm3)~* Patients with hypotension (with systolic blood pressure of 80 mmHg or less)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cellsorba EX (Type: EXPERIMENTAL): None
- Sham treatment (Type: SHAM_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).